Clinical trial
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed…
NCT00107237 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00107237 |
|---|---|
| Title | AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme |
| Official title | A Phase IB/II Multicenter, Two-Arm, Dose-Escalation Study of Oral AEE788 Administered in Combination With Oral RAD001 on a Continuous Once Daily Dosing Schedule in Adult Patients With First or Second Recurrent or Relapsing Glioblastoma Multiforme |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | AEE788, everolimus |
| Enrollment | 16 |
| Start date | Oct 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Apr 6, 2005 |
| Last update posted | Jun 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: